Payment overview · 2025
General Payments
$347.92
11 reported records · 5 companies
Healthcare provider profile · identity verified
John Travis Miller, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · GUIN, AL · NPI 1376581157
Verified facts
What the public records show
CMS Open Payments records show John Travis Miller, D.O. received $347.92 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 71.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $247.39 | 71.1% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.95 | 11.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.78 | 7.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.78 | 6.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.02 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $347.92 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $178.93 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.95 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.13 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 46 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
67 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 640 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 585 | 126 |
| Amlodipine Besylate | Amlodipine Besylate | 541 | 139 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 509 | 81 |
| Atorvastatin Calcium | Atorvastatin Calcium | 415 | 118 |
| Omeprazole | Omeprazole | 331 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 326 | 83 |
| Lisinopril | Lisinopril | 279 | 72 |
| Losartan Potassium | Losartan Potassium | 276 | 74 |
| Escitalopram Oxalate | Escitalopram Oxalate | 274 | 62 |
| Metformin Hcl Er | Metformin Hcl | 261 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 257 | 67 |
| Tramadol Hcl | Tramadol Hcl | 253 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 251 | 61 |
| Glipizide Er | Glipizide | 237 | 61 |
| Meloxicam | Meloxicam | 236 | 65 |
| Lorazepam | Lorazepam | 209 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 197 | 49 |
| Furosemide | Furosemide | 172 | 59 |
| Potassium Chloride | Potassium Chloride | 163 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 159 | 46 |
| Trazodone Hcl | Trazodone Hcl | 154 | 39 |
| Cefdinir | Cefdinir | 151 | 118 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 37 |
| Carvedilol | Carvedilol | 142 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 138 | 43 |
| Allopurinol | Allopurinol | 134 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 134 | 21 |
| Alprazolam | Alprazolam | 133 | 15 |
| Simvastatin | Simvastatin | 131 | 31 |
| Famotidine | Famotidine | 124 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 123 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 119 | 39 |
| Azithromycin | Azithromycin | 116 | 101 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 54 |
| Amitriptyline Hcl | Amitriptyline Hcl | 108 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 108 | 14 |
| Pregabalin | Pregabalin | 107 | 23 |
| Eliquis | Apixaban | 99 | 25 |
| Clonazepam | Clonazepam | 95 | 25 |
| Temazepam | Temazepam | 94 | 13 |
| Enalapril Maleate | Enalapril Maleate | 93 | 21 |
| Metformin Hcl | Metformin Hcl | 91 | 26 |
| Montelukast Sodium | Montelukast Sodium | 89 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 20 |
| Atenolol | Atenolol | 82 | 18 |
| Warfarin Sodium | Warfarin Sodium | 80 | 16 |
| Bupropion Xl | Bupropion Hcl | 79 | 16 |
| Sertraline Hcl | Sertraline Hcl | 73 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 72 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 25 |
| Amoxicillin | Amoxicillin | 70 | 59 |
| Celecoxib | Celecoxib | 68 | 22 |
| Methocarbamol | Methocarbamol | 68 | 33 |
| Farxiga | Dapagliflozin Propanediol | 67 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 19 |
| Fluconazole | Fluconazole | 64 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 25 |
| Bupropion Hcl Sr | Bupropion Hcl | 60 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 50 |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 15 |
| Alendronate Sodium | Alendronate Sodium | 59 | 18 |
| Levofloxacin | Levofloxacin | 59 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 13 |
| Glimepiride | Glimepiride | 53 | 14 |
| Januvia | Sitagliptin Phosphate | 52 | 13 |
| Spironolactone | Spironolactone | 52 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 14 |
| Ibuprofen | Ibuprofen | 50 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 15 |
| Methylprednisolone | Methylprednisolone | 49 | 41 |
| Ramipril | Ramipril | 49 | 13 |
| Estradiol | Estradiol | 47 | 12 |
| Cephalexin | Cephalexin | 46 | 31 |
| Memantine Hcl | Memantine Hcl | 46 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 17 |
| Buspirone Hcl | Buspirone Hcl | 44 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 43 | suppressed |
| Trulicity | Dulaglutide | 43 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Lansoprazole | Lansoprazole | 39 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | 12 |
| Meclizine Hcl | Meclizine Hcl | 35 | 18 |
| Donepezil Hcl | Donepezil Hcl | 34 | 11 |
| Primidone | Primidone | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Levemir | Insulin Detemir | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Mupirocin | Mupirocin | 23 | 17 |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Baclofen | Baclofen | 22 | 11 |
| Colestipol Hcl | Colestipol Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Prednisone | Prednisone | 22 | 17 |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 14 |
| Cilostazol | Cilostazol | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 18 |
| Valacyclovir | Valacyclovir Hcl | 19 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 13 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Nystatin | Nystatin | 18 | 12 |
| Sucralfate | Sucralfate | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 15 |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | 11 |
| Modafinil | Modafinil | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $347.92 · 11 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, Ozempic, TEZSPIRE, TRELEGY ELLIPTA, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error